AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
Log in

NASDAQ:CORVCorrevio Pharma Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.42
0.00 (0.00 %)
(As of 07/2/2020)
Add
Compare
Today's Range
$0.42
Now: $0.42
$0.42
50-Day Range
$0.39
MA: $0.41
$0.42
52-Week Range
$0.21
Now: $0.42
$2.79
VolumeN/A
Average Volume5.35 million shs
Market Capitalization$27.79 million
P/E RatioN/A
Dividend YieldN/A
Beta0.08
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CORV
CUSIPN/A
CIKN/A
Phone604-677-6905

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.63 million
Book Value($0.02) per share

Profitability

Net Income$-35,180,000.00
Net Margins-107.81%

Miscellaneous

Employees133
Market Cap$27.79 million
Next Earnings DateN/A
OptionableOptionable

Receive CORV News and Ratings via Email

Sign-up to receive the latest news and ratings for CORV and its competitors with MarketBeat's FREE daily newsletter.

Correvio Pharma (NASDAQ:CORV) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Correvio Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Correvio Pharma in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Correvio Pharma.

How were Correvio Pharma's earnings last quarter?

Correvio Pharma Corp (NASDAQ:CORV) released its quarterly earnings results on Monday, March, 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.06. The firm earned $11.33 million during the quarter, compared to the consensus estimate of $11.52 million. Correvio Pharma had a negative net margin of 107.81% and a negative return on equity of 2,128.82%. View Correvio Pharma's earnings history.

What price target have analysts set for CORV?

5 analysts have issued 1-year price targets for Correvio Pharma's shares. Their forecasts range from $1.60 to $7.00. On average, they expect Correvio Pharma's stock price to reach $4.87 in the next year. This suggests a possible upside of 1,059.0% from the stock's current price. View analysts' price targets for Correvio Pharma.

Has Correvio Pharma been receiving favorable news coverage?

News stories about CORV stock have trended negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Correvio Pharma earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Correvio Pharma.

Who are some of Correvio Pharma's key competitors?

What other stocks do shareholders of Correvio Pharma own?

Who are Correvio Pharma's key executives?

Correvio Pharma's management team includes the following people:
  • Dr. Mark H. N. Corrigan, CEO & Director (Age 62)
  • Mr. Justin A. Renz CPA, MST, M.S.T., MBA, CFO & Pres (Age 48)
  • Ms. Sheila M. Grant, Chief Operating Officer
  • Mr. David D. McMasters, Chief Compliance Officer & Gen. Counsel (Age 61)
  • Mr. Hugues Sachot, Chief Commercial Officer

What is Correvio Pharma's stock symbol?

Correvio Pharma trades on the NASDAQ under the ticker symbol "CORV."

What is Correvio Pharma's stock price today?

One share of CORV stock can currently be purchased for approximately $0.42.

How big of a company is Correvio Pharma?

Correvio Pharma has a market capitalization of $27.79 million and generates $32.63 million in revenue each year. The company earns $-35,180,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Correvio Pharma employs 133 workers across the globe.

What is Correvio Pharma's official website?

The official website for Correvio Pharma is www.correvio.com.

How can I contact Correvio Pharma?

Correvio Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The company can be reached via phone at 604-677-6905 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.